AstraZeneca vaccine: Blood clots are “extremely rare” and benefits outweigh risks, regulators conclude-Reference-Cited by-同舟云学术

AstraZeneca vaccine: Blood clots are “extremely rare” and benefits outweigh risks, regulators conclude

Published:2021-04-08 Issue: Volume: Page:n931
ISSN:1756-1833
Container-title:BMJ
language:en
Short-container-title:BMJ

Author:

Mahase Elisabeth

Publisher

BMJ

Subject

General Engineering

Reference3 articles.

1. Medicine: before COVID-19, and after

2. National Institute for Health and Care Excellence. DVT prevention for travellers: summary. Revised Aug 2018. https://cks.nice.org.uk/topics/dvt-prevention-for-travellers/#:~:text=The%20annual%20incidence%20of%20DVT,is%20prolonged%20seating%20and%20immobility.

3. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global and regional burden of vaccine‐induced thrombotic thrombocytopenia, 1969–2023: Comprehensive findings with critical analysis of the international pharmacovigilance database;European Journal of Haematology;2024-06-11

2. Prediction of new likely emergent amino acid point mutations from USA, UK, Italy, France, Brazil, and India SARS-CoV-2 variants: a possible source for more reliable cocktail coronavirus vaccine;RPS Pharmacy and Pharmacology Reports;2024-01-01

3. Harnessing Nanovaccines for Effective Immunization─A Special Concern on COVID-19: Facts, Fidelity, and Future Prospective;ACS Biomaterials Science & Engineering;2023-12-14

4. Intervention Trials;Handbook of Epidemiology;2023-11-21

5. Public Perception of the Chemical Composition of Covid-19 Vaccine that Hinders the Implementations of COVID-19 Vaccination in Indonesia;Journal of Biomimetics, Biomaterials and Biomedical Engineering;2023-11-03